

Executive Session Minutes
of the
Maryland Commission on Kidney Disease
October 24, 2013

Upon motion made by Commissioner Modi and seconded by Commissioner Jaar, Chairman Gimenez called the meeting to order at 3:45 p.m.

The Meeting was held under the authority of Section 10-508(a) of the State Government Article.

In attendance, in addition to Chairman Gimenez , were Commissioners Frederick, Jaar, Kraus, Light, Modi, Rayfield, and Stankovic.

Eva Schwartz, Executive Director and Donna Adcock, RN, Surveyor attended representing Commission staff.

Also attending was Leslie Schulman, Commission Counsel.

In attendance as a Commission invited guest was Carol Manning, Chief, DHMH-Kidney Disease Program.

Item One

The Commission discussed the clinical pros and cons of adding Astragraf XL (Tacrolimus extended-release capsules) to the Kidney Disease Program's Formulary. After discussion lead by Dr. Kraus concerning factors directly related to safety, improved efficacy or therapeutic benefits when used in combination with already approved medications, and cost, the Commission unanimously voted to not approve adding Astragraf XL to the formulary at the present time. Ratification of the vote will take place at the next Public Session.

Item Two

Eva Schwartz updated the Commission on the progress of working with the Office of Health Care Quality to resurvey a dialysis facility that the Commission had repeatedly found to be significantly deficient in its nurse staffing and infection control. This facility has been surveyed twice in the past 12 months, by Donna Adcock, and was determined to be noncompliant with Commission regulatory standards. After discussion ensued, the Commissioners directed Commission staff to keep the facility under the radar screen and to provide them with periodic progress updates.

Upon Motion made, the Executive Session was adjourned at 4:11 p.m.